PD1 and PARP for Maintenance Therapy in NSLLC

Summary

PARP inhibitor and PD1 in lung squamous cell carcinoma The current study will compare PD1 plus maintenance PARP for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: respect to progression-free survival (PFS) per RECIST 1.1 by blinded independent clinical review (BICR). Overall survival (OS).

Timeline

Start

2022-06-20

Primary completion

2022-06-21

Completion

2025-04-01

Drugs

Indications